Table 1 Characteristics of the population at inclusion
N = 330, unless otherwise indicated | Mean ± SD (n) or % (n) |
|---|---|
Age (years) | 45.2 ± 10.2 |
Sex-ratio (male/female) | 3.6 (258/72) |
Single/divorced/widowed (324) | 69.1 % (224) |
Lifestyle (324) | |
Couple | 31.5 % (102) |
Living alone | 39.1 % (127) |
Other (family, friends…) | 29.4 % (97) |
With a professional activity | 55.4 % (174) |
Resources (327) | |
Own or from family | 67.9 (222) |
Social | 32.1 (105) |
Smokers | 80.2 % (186) |
With psychiatric co-morbidity | 60.9 % (200) |
Type of psychiatric comorbidity | |
None | 39.1 % (129) |
Dementia | 1.5 % (5) |
Psychosis | 4.6 % (15) |
Mood and affective disorder | 30.6 % (101) |
Anxiety disorder | 5.5 % (18) |
Personality disorder | 26.1 % (87) |
With somatic comorbidity | 7.6 % (25) |
Global Assessment of Functioning | 49.14 ± 15.60 |
AUDIT (312) | 26.9 ± 7.7 |
Risk use (score ≤7) | 2.2 (7) |
Harmful use (7< score <13) | 2.2 (7) |
Dependence (score ≥13) | 95.5 (298) |
BDI score (308) | 13.5 ± 7.1 |
BDI categories | |
Absent | 5.8 (18) |
Slight | 16.2 (50) |
Moderate | 41.6 (128) |
Severe | 36.4 (112) |
MCV (µm3) | 97.9 ± 6.2 |
% >normal values (n) | 55.9 (181) |
SGOT (UI/L) | 47.4 ± 53.5 |
% >normal values (n) | 39.3 (129) |
SGPT (UI/L) | 42.5 ± 41.5 |
% >normal values (n) | 41.5 (136) |
GGT (UI/L) (mean ± SD) | 222.7 ± 408.2 |
% >normal values (n) | 61.6 (202) |
Current psychotropic treatment | |
Neuroleptics | 14.2 % (47) |
Atypical antipsychotics | 14.5 % (48) |
Thymoregulators | 7.8 % (26) |
Antidepressants | 52.7 % (174) |
Anxiolytics | 90 (297) |
Benzodiazepines | 88.4 % (292) |
Related to benzodiazepines | 23.0 % (76) |